<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The discovery of a series of non-<z:chebi fb="7" ids="16670">peptide</z:chebi> factor Xa (FXa) inhibitors incorporating 3-(S)-amino-2-<z:chebi fb="0" ids="38275">pyrrolidinone</z:chebi> as a central template is described </plain></SENT>
<SENT sid="1" pm="."><plain>After identifying compound 4, improvements in in vitro potency involved modifications of the liphophilic group and optimizing the angle of presentation of the <z:chebi fb="0" ids="2634">amidine</z:chebi> group to the S1 pocket of FXa </plain></SENT>
<SENT sid="2" pm="."><plain>These studies ultimately led to compound RPR120844, a potent inhibitor of FXa (K(i) = 7 nM) which shows selectivity for FXa over trypsin, thrombin, and several fibrinolytic serine proteinases </plain></SENT>
<SENT sid="3" pm="."><plain>RPR120844 is an effective <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> in both the rat model of FeCl(2)-induced carotid artery <z:mp ids='MP_0005048'>thrombosis</z:mp> and the rabbit model of jugular vein <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation </plain></SENT>
</text></document>